Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017 Summary Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 3, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Central Nervous System, Dermatology and Metabolic Disorders which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Female Contraception, Vasomotor Symptoms of Menopause (Hot Flashes), Bipolar Disorder (Manic Depression), Ductal Carcinoma In Situ, Encephalopathy, Hormone Sensitive Breast Cancer, Metastatic Prostate Cancer, Multiple Sclerosis, Neurology, Osteoporosis, Ovarian Cancer, Prostate Cancer, Vaginal Atrophy (Atrophic Vaginitis) and Vulvar Atrophy. Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects - The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview 8 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 12 Products under Development by Universities/Institutes 15 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment 17 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development 23 Arvinas Inc 23 AstraZeneca Plc 23 Atossa Genetics Inc 23 Chamaeleo Pharma NV 24 EndoCeutics Inc 24 Genentech Inc 25 H3 Biomedicine Inc 25 Mithra Pharmaceuticals SA 26 Novartis AG 26 Nuevolution AB 27 Shenogen Pharma Group Ltd 27 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles 28 (acolbifene hydrochloride + prasterone) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 (drospirenone + estetrol) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 acolbifene hydrochloride - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Endoxifen - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Estetrol - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 fosfestrol - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 fulvestrant - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 fulvestrant - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 GDC-0927 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 H-3B6545 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Loseasonique - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 NDC-1308 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecule to Antagonize Estrogen Receptor Alpha for Metastatic Breast Cancer - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 SNG-8023 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 SR-16234 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 sulfestrol - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 TTC-352 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 VP-128 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products 64 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products 66 Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones 67 Featured News & Press Releases 67 Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer 67 Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective 67 Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer 68 Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study 69 Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Substudy 69 Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer 70 Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study 71 Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 71 Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal 72 Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer 72 Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 73 Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 74 May 12, 2017: Mithra to Initiate PK Study for Estelle 74 May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study 75 Mar 09, 2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indication, H2 2017 11 Number of Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14 Number of Products under Investigation by Universities/Institutes, H2 2017 15 Products under Investigation by Universities/Institutes, H2 2017 16 Number of Products by Stage and Mechanism of Actions, H2 2017 18 Number of Products by Stage and Route of Administration, H2 2017 20 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by Arvinas Inc, H2 2017 23 Pipeline by AstraZeneca Plc, H2 2017 23 Pipeline by Atossa Genetics Inc, H2 2017 24 Pipeline by Chamaeleo Pharma NV, H2 2017 24 Pipeline by EndoCeutics Inc, H2 2017 25 Pipeline by Genentech Inc, H2 2017 25 Pipeline by H3 Biomedicine Inc, H2 2017 25 Pipeline by Mithra Pharmaceuticals SA, H2 2017 26 Pipeline by Novartis AG, H2 2017 27 Pipeline by Nuevolution AB, H2 2017 27 Pipeline by Shenogen Pharma Group Ltd, H2 2017 27 Dormant Products, H2 2017 64 Dormant Products, H2 2017 (Contd..1), H2 2017 65 Discontinued Products, H2 2017 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
